Novartis Reports Strong Quarter and Raises Earnings Guidance

1 Mins read

Novartis, the Swiss pharmaceutical giant, has announced higher net profit and sales for the third quarter of the year, driven by strong sales of key drugs. As a result, the company has increased its full-year earnings guidance for the third time this year.

Revised Earnings Guidance

Novartis now expects its core operating profit to grow by a percentage in the mid to high teens range for the year. This is a more optimistic outlook compared to the previous growth rate from low double percentage digits to mid teens, excluding the generics unit Sandoz, which was spun off earlier this month.

Positive Sales Projections

The company has also reiterated its expectation for a high single digit growth in net sales for 2023.

Financial Performance

In the third quarter, Novartis reported a net profit of $1.76 billion, an increase from $1.57 billion in the same period last year. Net sales for the quarter reached $11.78 billion, up from $10.49 billion.

Strong Performance of Key Drugs

Novartis’ Chief Executive, Vas Narasimhan, highlighted the strong performance of their growth drivers in the market. Drugs such as Kesimpta, Entresto, Kisqali, and Pluvicto continue to perform well.

Core Operating Income Growth

Excluding exceptional items, core operating income from continuing operations showed a 21% increase to $4.41 billion.

Related posts

Government Matching Contribution for Retirement Savings

2 Mins read
According to researchers, nearly 22 million Americans are set to benefit from a new government matching contribution initiative aimed at enhancing retirement…

Oil Market Update

1 Mins read
Oil Market Update On Tuesday, crude oil futures prices were lower, while refined product contracts were experiencing a second consecutive day of…

Carrier Global Sells Industrial Fire Business

1 Mins read
Carrier Global Sells Industrial Fire Business for $1.425 Billion Carrier Global has announced the sale of its industrial fire business to private-equity…

Leave a Reply

Your email address will not be published. Required fields are marked *